- GW Pharma’s seizure medicine Epidiolex handily surpassed Wall Street forecasts for sales during the first quarter, and the biotech gave reason for further optimism by announcing Monday that the cannabis-derived drug succeeded in late-stage study aimed at expanding its market.
- The Phase 3 trial showed Epidiolex significantly reduced seizure rates in patients with tuberous sclerosis complex, or TSC, compared to placebo. The drugmaker plans to file a supplemental drug application with the Food and Drug Administration in the fourth quarter this year.
- From January to March, Epidiolex posted $33.5 million in U.S. net sales, double the market consensus of $16 million. Together, the positive financial and clinical news helped drive GW’s stock up nearly 9% at market open Tuesday.
While $33 million would barely register on the books of many large drugmakers, GW Pharma’s progress in launching Epidiolex (cannabidiol) has given some early proof to the promise of cannabis-based drugs.
“This performance reflects